Jan Lundberg, AstraZeneca Executive VP, Head of Global Discovery Research, sat down with "The Pink Sheet" DAILY last month in Washington, D.C. In this interview he talks about the follow-on compound to Exanta, our cancer and diabetes projects, the collaboration with our biologicals unit MedImmune, translational science, personalized medicine and the need for differentiation.

Read the full interview